Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy

Lignende værker

• Loss of HER2 Amplification Following Trastuzumab-based Neoadjuvant Systemic Therapy and Survival Outcomes
  af: Mittendorf, Elizabeth A., et al.
  Udgivet: (2009)
• Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer
  af: Kim, M. M., et al.
  Udgivet: (2013)
• Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab
  af: Peintinger, F., et al.
  Udgivet: (2008)
• Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab
  af: Kogawa, Takahiro, et al.
  Udgivet: (2020)
• High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer
  af: Kogawa, Takahiro, et al.
  Udgivet: (2016)